On Monday, President Donald Trump signed an executive order aimed at lowering prescription drug prices for Americans. This move is seen as a crucial step in reforming the current drug pricing system.
During the announcement, Trump, along with Robert F. Kennedy Jr. from the Department of Health and Human Services, condemned the existing system, criticizing the profits made by large pharmaceutical companies. Trump emphasized that the U.S. would no longer support high prices that seem to benefit foreign markets at the expense of American consumers.
He remarked, “The U.S. funds around three-quarters of global drug profits while representing less than 5% of the world’s population. This disparity is largely a result of a system designed to subsidize drug manufacturers in other countries.”
Trump went on to explain that the principle of the order is straightforward: “Americans will pay the lowest price available for drugs in other developed countries, which could mean a reduction of 50 to 90% for many medications almost immediately.”
He also stated, “Today marks a shift; the U.S. will no longer be the financial backbone for foreign healthcare systems.”
RFK Jr. shared his thoughts on the order, expressing his surprise and support. “I honestly didn’t think I would see this happen in my lifetime,” he said, highlighting Trump’s commitment to standing up for American citizens against pharmaceutical interests.
“Unlike many politicians, he can’t be bought, and he genuinely stands for the American people,” RFK Jr. noted, referencing prominent political figures and their ties to big money.
The White House is also looking to explore ways to counteract tactics used by pharmaceutical companies to maintain elevated prices. This plan involves directing U.S. trade representatives to prevent unfair pricing practices from affecting the American market.
In addition, the Secretary of Health and Human Services is tasked with creating a system allowing American patients to purchase medications directly from manufacturers at favorable prices, bypassing middlemen. If a manufacturer fails to comply, the Secretary is instructed to propose rules ensuring adherence to the new pricing standards.
